Literature DB >> 7938331

Short-term psychotherapy of depressive disorders: current status and future directions.

R B Jarrett1, A J Rush.   

Abstract

Depressive disorders can affect all aspects of a person's functioning and are often associated with significant psychosocial impairment. Such psychosocial problems promote studies of the efficacy of short-term psychotherapy for depressive disorders. This report summarizes the literature on acute-phase, short-term psychotherapy for adult outpatients with major depressive disorder and is an updated component of a larger review commissioned by the United States Public Health Services Agency for Health Care Policy and Research (AHCPR review on "Short-term Psychotherapy for Depression," Jarrett and Maguire [1991]; Jarrett and Down [in press] during the preparation of the Clinical Practice Guidelines in primary care (Depression Guideline Panel 1993). The short-term psychotherapies reviewed here and studied most often include behavior therapy, cognitive therapy, interpersonal psychotherapy, and brief dynamic psychotherapy, which all aim to reduce depressive symptoms. We comment on the state of the literature and raise some of the questions which await data.

Entities:  

Mesh:

Year:  1994        PMID: 7938331     DOI: 10.1080/00332747.1994.11024675

Source DB:  PubMed          Journal:  Psychiatry        ISSN: 0033-2747            Impact factor:   2.458


  15 in total

1.  Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.

Authors:  Robin B Jarrett; Michael E Thase
Journal:  Contemp Clin Trials       Date:  2010-05-06       Impact factor: 2.226

Review 2.  A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders.

Authors:  Marcelo Feijo de Mello; Jair de Jesus Mari; Josue Bacaltchuk; Helen Verdeli; Richard Neugebauer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 3.  Awareness, diagnosis, and treatment of depression.

Authors:  L S Goldman; N H Nielsen; H C Champion
Journal:  J Gen Intern Med       Date:  1999-09       Impact factor: 5.128

4.  Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.

Authors:  R B Jarrett; M Schaffer; D McIntire; A Witt-Browder; D Kraft; R C Risser
Journal:  Arch Gen Psychiatry       Date:  1999-05

Review 5.  Cognition in mania and depression: psychological models and clinical implications.

Authors:  Samuel R Chamberlain; Barbara J Sahakian
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 5.285

6.  A randomized controlled trial of cognitive-behavioral treatment for depression versus relaxation training for alcohol-dependent individuals with elevated depressive symptoms.

Authors:  Richard A Brown; Susan E Ramsey; Christopher W Kahler; Kathleen M Palm; Peter M Monti; David Abrams; Maryella Dubreuil; Alan Gordon; Ivan W Miller
Journal:  J Stud Alcohol Drugs       Date:  2011-03       Impact factor: 2.582

7.  An adaptation of the Interpersonal Problem Areas Rating Scale: pilot and interrater agreement study.

Authors:  Ana Claudia Fontes de Andrade; Ellen Frank; Francisco Lotufo Neto; Patricia R Houck
Journal:  Braz J Psychiatry       Date:  2008-12       Impact factor: 2.697

8.  Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C.

Authors:  Louise Balfour; Curtis Cooper; John Kowal; Giorgio A Tasca; Amy Silverman; Marie Kane; Gary Garber
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

9.  Separate personality traits from states to predict depression.

Authors:  Lee Anna Clark; Jeffrey Vittengl; Dolores Kraft; Robin B Jarrett
Journal:  J Pers Disord       Date:  2003-04

10.  Improvement in social-interpersonal functioning after cognitive therapy for recurrent depression.

Authors:  J R Vittengl; L A Clark; R B Jarrett
Journal:  Psychol Med       Date:  2004-05       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.